Abstract:Background: Esketamine, the first Food and Drug Administration-approved fast-acting antidepressant, has limited use because of its addictive properties. Although the combination of dextromethorphan and bupropion partially addresses the limitations of esketamine, concerns remain regarding neurologic side effects related to dextromethorphan metabolites, and seizure risks associated with high-dose bupropion. SAL0114, a novel formulation combining deuterated dextromethorphan (in which hydrogen atoms are replaced with deuterium) with bupropion, seeks to enhance dextromethorphan stability through deuteration of its metabolic sites. This approach is expected to increase antidepressant efficacy, reduce metabolite-induced safety issues, and allow for lower bupropion dosages. Methods: Radioligand competition binding assays were used to evaluate the impact of deuterium substitution on the in vitro activity of dextromethorphan and its metabolite, dextrorphan. In vitro hepatic microsomal stability and in vivo mouse pharmacokinetic assays were performed to assess the effects of deuteration on dextromethorphan stability. Two mouse models of behavioral despair were used to determine the antidepressant and synergistic effects of deuterated dextromethorphan and bupropion. Additionally, a reserpine-induced hypothermia rat model and an ammonia-induced cough mouse model were used to assess the in vivo effects from a pathological perspective. Results: Deuterated dextromethorphan maintained the same in vitro activity as dextromethorphan while exhibiting twice the metabolic stability both in vitro and in vivo. Combination with bupropion further improved its in vivo stability, increasing the exposure by 2.4 times. The combination demonstrated efficacy and synergistic effects in all tested animal models, showing superior efficacy compared with the dextromethorphan-bupropion combination. Conclusion: Deuteration improved dextromethorphan metabolic stability without altering its in vitro activity. Bupropion enhanced this stability and synergistically boosted the antidepressant effect by increasing deuterated dextromethorphan exposure in vivo. This enhanced metabolic stability suggests a reduction in dextromethorphan metabolites associated with clinical neurological side effects. Consequently, SAL0114 is hypothesized to offer improved efficacy and safety compared with the non-deuterated combination, potentially allowing for lower bupropion dosages. Further clinical studies are required to confirm these preclinical findings.

Efficacy Of Dextromethorphan For The Treatment Of Depression: A Systematic Review Of Preclinical And Clinical Trials

Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials

Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder

Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder

Glutamatergic Modulators for Major Depression from Theory to Clinical Use

[Out-patient treatment of venous trophic ulcers using Baneocin].

Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol

SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile

Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy

Efficacy and dose-response relationships of antidepressants in the acute treatment of major depressive disorders: a systematic review and network meta-analysis

Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder

Emerging drugs for the treatment of major depressive disorder

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

Rapid-acting antidepressants targeting modulation of the glutamatergic system: clinical and preclinical evidence and mechanisms

Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials

ARMOR: analyzer for reducing module operational risk

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

Managing constipation: a focus on care and treatment in the palliative setting.

New and emerging treatments for major depressive disorder

Carbon dioxide lasers: a broader perspective.

Sports injury research.